Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002157327 | SCV002340105 | likely benign | not provided | 2024-10-17 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV002157327 | SCV003822492 | uncertain significance | not provided | 2020-03-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV005301101 | SCV005957244 | uncertain significance | Inborn genetic diseases | 2024-12-11 | criteria provided, single submitter | clinical testing | The c.2024G>A (p.R675Q) alteration is located in exon 10 (coding exon 9) of the ACAN gene. This alteration results from a G to A substitution at nucleotide position 2024, causing the arginine (R) at amino acid position 675 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004553653 | SCV004765601 | likely benign | ACAN-related disorder | 2022-05-16 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |